Evidence map›Paper›PMID 41131148›Full record

ArticleNature biotechnology2025

Overcoming barriers to the wide adoption of single-cell large language models in biomedical research.

Fang Xie, Bingkang Zhao, Songxiang Xu, Zehua Wang, James J Moon, Lana X Garmire

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fang Xie *Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Bingkang Zhao *Department of Rheumatology and Immunology, Second Affiliated Hospital and Centre of Biomedical Systems and Informatics, University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Songxiang Xu *Department of Rheumatology and Immunology, Second Affiliated Hospital and Centre of Biomedical Systems and Informatics, University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Zehua Wang *Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Lana X GarmireDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA. lgarmire@umich.edu.ORCID http://orcid.org/0000-0002-4654-2126

Funding

Engineered Nano-formulations for STING ActivationR01DE031951 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yu Leo Lei, James J. Moon · 2022 to 2026
$3.1M
Biomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7M
Cancer precision medicine through spatially informative single cell image and transcriptomics data analysisR01LM012373 · NLM · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARMIRE, LANA X · 2016 to 2024
$2.4M
Personalized cancer drug repurposing using single cell RNA-Seq dataR03OD039978 · OD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARMIRE, LANA X · 2025 to 2025
$303k
NCI NIH HHS R01 CA271799NIDCR NIH HHS R01 DE031951NIH HHS R03 OD039978NLM NIH HHS R01 LM012373
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41131148
PMCPMC13520874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.